Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00003281
First received: November 1, 1999
Last updated: July 23, 2008
Last verified: July 2007